Poor
Mostly Aligned
Patient Risk:
Low
Summary
Most claims are not supported by the provided FDA label sections, and one clinical-use claim is only partially supported. Multiple statements (patent/exclusivity, Ozempic trade name, developer/patent ownership) are absent from the provided label text, and key label safety/dosing sections were not provided, limiting full alignment assessment.
Category Scores
Accurate Statements
Unsupported Statements
The patent for semaglutide is set to expire on March 6, 2035.
No patent/exclusivity/expiration information is present in the provided label sections.
Semaglutide is marketed under the trade name Ozempic among others.
The provided label sections do not mention Ozempic or any cross-brand trade-name information.
Semaglutide was developed by Novo Nordisk.
The provided label sections do not state development history.
Semaglutide's original patent is owned by Novo Nordisk.
The provided label sections do not include patent ownership information.
Contradictions
Low
AI Statement
Semaglutide is used to treat type 2 diabetes and obesity.
Label Reference
1 INDICATIONS AND USAGE (provided excerpt for WEGOVY): indications include CV risk reduction in adults with established CV disease and obesity/overweight, weight reduction in adults/pediatric patients 12+ with obesity and in adults with overweight plus comorbidity, and MASH with moderate-to-advanced fibrosis; the provided excerpt does not include a type 2 diabetes indication.
Important Omissions
No dosing/administration, boxed warnings, full contraindications, or complete warnings/precautions content was provided for evaluation beyond a single warnings subsections (5.6) excerpt.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements are primarily about patent/trade name/developer history and a partially supported indication; however, key safety/dosing label sections required to assess clinical risk alignment were not fully provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not supported by the provided FDA label sections, and the type 2 diabetes portion of the indication claim is not supported by the provided WEGOVY indications excerpt.
Suggested Improvement
Limit statements to the provided label content: describe WEGOVY indications (CV risk reduction and weight reduction, and the provided MASH indication) without adding unsupported patent/trade name/developer/patent ownership details; avoid asserting a type 2 diabetes indication unless present in the provided label text.